Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: GlobeNewswire
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrfiend, M.D., of RUSH University Medical Center at the 2024 IRSF Rett Syndrome Scientific Meeting on Wednesday, June 19, 2024, at 11:00 AM Mountain Time DALLAS, June 12, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will host a webcast on Tuesday, June 18, 2024, to discuss new clinical data from the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome, as well as provide a program update. The data will also be presented at the 2024 International Rett Syndrome Founda
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.MarketBeat
TSHA
Earnings
- 5/14/24 - Beat
TSHA
Sec Filings
- 6/26/24 - Form 8-K
- 6/26/24 - Form 424B5
- 6/18/24 - Form 8-K
- TSHA's page on the SEC website